Index Entries

Reaz Mahmud, Mujibur Rahman, Iftikher Alam, Kazi Gias Uddin Ahmed, A.K.M. Humayon Kabir, S.K. Jakaria Been Sayeed, Mohammad Aftab Rassel, Farhana Binte Monayem, Md Shahidul Islam, Mohammad Monirul Islam, Anindita Das Barshan, Mohammad Mahfuzul Hoque, Uzzal Mallik, Mohammad Abdullah Yusuf, and Mohammad Zaid Hossain
May 13, 2021
Journal of International Medical Research
Dhaka Medical College (Bangladesh)

"Objective: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection.

Methods: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups...

Results: The median recovery time was 7 (4–10, treatment group) and 9 (5–12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60–0.90). The number of patients with a ≤7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04–0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group.

Discussion: In the present study, patients with mild or moderate COVID-19 infection treated with ivermectin in combination with doxycycline generally recovered 2 days earlier than those treated with placebo. The proportion of patients responding within 7 days of treatment was significantly higher in the treatment group than in the placebo group. The proportions of patients who remained symptomatic after 12 days of illness and who experienced disease progression were significantly lower in the treatment group than in the placebo group. The proportion of patients who remained RT-PCR positive for COVID-19 was also lower in the treatment group than in the placebo group."

document
COVID-19,ivermectin,medical treatments,pharmaceuticals